Has pharmacogenomics arrived?

The FDA yesterday linkurl:updated the label;http://www.fda.gov/bbs/topics/NEWS/2007/NEW01684.html on a widely used blood thinner, warfarin, to include information about how a patient's genes will linkurl:predict response;http://www.the-scientist.com/article/display/14864/ to the drug. Patients with certain genetic variations should receive a lower dose of the drug, according to the added text. Although a handful of drugs already note such genetic information on their labels, most of these are

By | August 17, 2007

The FDA yesterday linkurl:updated the label;http://www.fda.gov/bbs/topics/NEWS/2007/NEW01684.html on a widely used blood thinner, warfarin, to include information about how a patient's genes will linkurl:predict response;http://www.the-scientist.com/article/display/14864/ to the drug. Patients with certain genetic variations should receive a lower dose of the drug, according to the added text. Although a handful of drugs already note such genetic information on their labels, most of these are cancer drugs, which are used by a well-circumscribed set of patients. Warfarin is much more widely prescribed - about two million people start taking it each year, according to the FDA press release. Although the drug is notorious for its dosing difficulties, it has been around for more than 50 years, and doctors are used to managing dosing by trial and error. Though FDA commissioner Andrew C. von Eschenbach in the agency's statement calls the label change "one step in the FDA's commitment to linkurl:personalized medicine;http://www.the-scientist.com/article/display/18849/ ," what exactly doctors and patients are supposed to do with this genetic information is not entirely clear. A front-page linkurl:article;http://online.wsj.com/article/SB118722561330199147.html in the Wall Street Journal yesterday noted that although genetic tests can identify who has certain genetic variants, researchers have heatedly debated whether enough is known about these variations to determine what they mean for the patient. One clinical researcher quoted in the article, linkurl:Ann Wittkowsky;http://www.thrombosisclinic.com/en/11/84/373/ of the University of Washington, said that "It would be irresponsible and potentially harmful to suggest that testing be used, or even mentioned, in the label," adding that the testing is "fascinating science, but it is not yet ready for prime time."

Popular Now

  1. Running on Empty
    Features Running on Empty

    Regularly taking breaks from eating—for hours or days—can trigger changes both expected, such as in metabolic dynamics and inflammation, and surprising, as in immune system function and cancer progression.

  2. Athletes’ Microbiomes Differ from Nonathletes
  3. Stomach Cells Change Identity to Drive Precancerous State
  4. Mutation Linked to Longer Life Span in Men
AAAS